Maven Securities’s Standard BioTools LAB Stock Holding History

Maven Securities’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,000	Closed	-$177K	–	991
2024 Q2	$177K	Buy	+100,000	New	+$244K	﹤0.01%	892

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities's LAB Position: Q3 2024 in Review

Maven Securities sold out of Standard BioTools (LAB) in Q3 2024, closing a stake of 100,000 shares — an estimated $177K sold.

Maven Securities first reported a position in LAB in Q2 2024 and held it in 1 quarter. The position peaked at $177K in Q2 2024. 141 funds tracked by Wall St. Rank hold LAB as of Q3 2024.

Maven Securities reported no remaining Standard BioTools position as of Q3 2024 after selling out during the quarter.
Maven Securities sold 100,000 Standard BioTools shares in Q3 2024, an estimated $177K.
Maven Securities first reported a position in Standard BioTools in Q2 2024 and held it in 1 quarter.
Maven Securities's Standard BioTools position peaked at $177K in Q2 2024.
141 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2024.

Based on Maven Securities's 13F filing for Q3 2024, filed 14 Nov 2024.